JP2017513842A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513842A5 JP2017513842A5 JP2016561879A JP2016561879A JP2017513842A5 JP 2017513842 A5 JP2017513842 A5 JP 2017513842A5 JP 2016561879 A JP2016561879 A JP 2016561879A JP 2016561879 A JP2016561879 A JP 2016561879A JP 2017513842 A5 JP2017513842 A5 JP 2017513842A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- atom
- salt
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014082057 | 2014-04-11 | ||
| JP2014082057 | 2014-04-11 | ||
| PCT/JP2015/061651 WO2015156417A1 (en) | 2014-04-11 | 2015-04-09 | Cyclopropanamine compound and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513842A JP2017513842A (ja) | 2017-06-01 |
| JP2017513842A5 true JP2017513842A5 (enExample) | 2018-05-24 |
| JP6470310B2 JP6470310B2 (ja) | 2019-02-13 |
Family
ID=53055078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561879A Expired - Fee Related JP6470310B2 (ja) | 2014-04-11 | 2015-04-09 | シクロプロパンアミン化合物およびその用途 |
Country Status (28)
| Country | Link |
|---|---|
| US (9) | US10053456B2 (enExample) |
| EP (1) | EP3129369A1 (enExample) |
| JP (1) | JP6470310B2 (enExample) |
| KR (1) | KR102359836B1 (enExample) |
| CN (1) | CN106459024B (enExample) |
| AR (1) | AR099994A1 (enExample) |
| AU (1) | AU2015244698B2 (enExample) |
| BR (1) | BR112016023382B1 (enExample) |
| CA (1) | CA2945085C (enExample) |
| CL (1) | CL2016002573A1 (enExample) |
| CR (1) | CR20160485A (enExample) |
| DO (1) | DOP2016000273A (enExample) |
| EA (1) | EA034197B1 (enExample) |
| EC (1) | ECSP16087256A (enExample) |
| IL (1) | IL248181B (enExample) |
| MA (1) | MA39732A (enExample) |
| MX (1) | MX375990B (enExample) |
| MY (1) | MY180575A (enExample) |
| NZ (1) | NZ725262A (enExample) |
| PE (1) | PE20161441A1 (enExample) |
| PH (1) | PH12016502016B1 (enExample) |
| SG (2) | SG11201608340UA (enExample) |
| TN (1) | TN2016000418A1 (enExample) |
| TW (1) | TWI669291B (enExample) |
| UA (1) | UA122205C2 (enExample) |
| UY (1) | UY36071A (enExample) |
| WO (1) | WO2015156417A1 (enExample) |
| ZA (1) | ZA201607773B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ723203A (en) | 2014-02-13 | 2020-08-28 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
| EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| KR102421235B1 (ko) | 2014-02-13 | 2022-07-15 | 인사이트 코포레이션 | Lsd1 저해제로서 사이클로프로필아민 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| SG11201608340UA (en) * | 2014-04-11 | 2016-11-29 | Takeda Pharmaceuticals Co | Cyclopropanamine compound and use thereof |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016083458A1 (en) | 2014-11-26 | 2016-06-02 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Reprogramming-based models of neurodevelopmental disorders and uses thereof |
| UA122688C2 (uk) | 2015-04-03 | 2020-12-28 | Інсайт Корпорейшн | Гетероциклічні сполуки як інгібітори lsd1 |
| AU2016275702A1 (en) | 2015-06-12 | 2017-12-21 | Oryzon Genomics, S.A. | Biomarkers associated with LSD1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| JP7427363B2 (ja) | 2015-08-12 | 2024-02-05 | インサイト・ホールディングス・コーポレイション | Ｌｓｄ１阻害剤の塩 |
| US10059668B2 (en) | 2015-11-05 | 2018-08-28 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
| SG11201805645QA (en) | 2015-12-29 | 2018-07-30 | Mirati Therapeutics Inc | Lsd1 inhibitors |
| BR112018013074A2 (en) | 2015-12-30 | 2018-12-11 | Novartis Ag | immune effector cell therapies with enhanced efficacy |
| WO2017130933A1 (ja) * | 2016-01-25 | 2017-08-03 | 国立大学法人熊本大学 | 神経変性疾患治療剤 |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| WO2017158136A1 (en) | 2016-03-16 | 2017-09-21 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| US10166221B2 (en) | 2016-04-22 | 2019-01-01 | Incyte Corporation | Formulations of an LSD1 inhibitor |
| WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| WO2018083138A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| SI3661510T1 (sl) | 2017-08-03 | 2025-03-31 | Oryzon Genomics, S.A. | Postopki zdravljenja vedenjskih sprememb |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| CN109553591B (zh) * | 2019-01-15 | 2020-12-15 | 山东安信制药有限公司 | 一种富马酸喹硫平中间体的制备方法 |
| US20220151999A1 (en) | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| US20220151998A1 (en) | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
| JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
| WO2022224267A1 (en) * | 2021-04-21 | 2022-10-27 | Natco Pharma Limited | Improved process for the preparation of 7-(morpholinyl)-2-(n-piperazinyl)methylthieno[2, 3-c]pyridine derivatives |
| CN113512031B (zh) * | 2021-07-01 | 2024-01-30 | 都创(上海)医药开发有限公司 | 一种lsd1酶抑制剂tak-418中间体化合物制备方法 |
| CN117164465B (zh) * | 2023-09-04 | 2025-07-01 | 郑州大学 | 一种苯基环丙胺类化合物及其制备方法和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002100399A1 (en) | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| CN1882529A (zh) | 2003-09-24 | 2006-12-20 | 梅特希尔基因公司 | 组蛋白脱乙酰基酶抑制剂 |
| CA2539117A1 (en) | 2003-09-24 | 2005-04-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
| CA2549660A1 (en) | 2003-12-15 | 2005-06-30 | Japan Tobacco Inc. | Cyclopropane compounds and pharmaceutical use thereof |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| US8993808B2 (en) * | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| WO2010143582A1 (ja) * | 2009-06-11 | 2010-12-16 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びlsd1阻害剤 |
| US8859555B2 (en) * | 2009-09-25 | 2014-10-14 | Oryzon Genomics S.A. | Lysine Specific Demethylase-1 inhibitors and their use |
| EP2486002B1 (en) * | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| MX2012012111A (es) | 2010-04-19 | 2013-05-30 | Oryzon Genomics Sa | Inhibidores de demetilasa-1 especifica de lisina y su uso. |
| AU2011244478B2 (en) | 2010-04-20 | 2014-07-17 | Fondazione IEO-CCM | Tranylcypromine derivatives as inhibitors of histone demethylase LSD1 and/or LSD2 |
| SI2598482T1 (sl) | 2010-07-29 | 2018-09-28 | Oryzon Genomics, S.A. | Inhibitorji demetilaze lsd1 na osnovi arilciklopropilamina in njihova medicinska uporaba |
| WO2012013727A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| JP2012036124A (ja) | 2010-08-06 | 2012-02-23 | Nagoya City Univ | Ｈｉｖ複製阻害剤 |
| US8709048B2 (en) * | 2010-08-20 | 2014-04-29 | Tongji University | Rod system for gradual dynamic spinal fixation |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| CA2831143C (en) * | 2011-03-25 | 2019-05-21 | Glaxosmithkline Intellectual Property Development Limited | Cyclopropylamines as lsd1 inhibitors |
| EP2741741A2 (en) | 2011-05-19 | 2014-06-18 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| US20140296255A1 (en) | 2011-05-19 | 2014-10-02 | Oryzong Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
| UA114406C2 (uk) * | 2011-08-09 | 2017-06-12 | Такеда Фармасьютікал Компані Лімітед | Похідні циклопропанаміну як інгібітори lsd1 |
| CN107266345B (zh) | 2011-10-20 | 2021-08-17 | 奥瑞泽恩基因组学股份有限公司 | 作为lsd1抑制剂的(杂)芳基环丙胺化合物 |
| RS58475B1 (sr) | 2011-10-20 | 2019-04-30 | Oryzon Genomics Sa | Jedinjenja (hetero)aril ciklopropilamina kao lsd1 inhibitori |
| US9751885B2 (en) | 2012-10-12 | 2017-09-05 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
| CN104042616B (zh) | 2014-02-20 | 2016-08-24 | 复旦大学附属眼耳鼻喉科医院 | 赖氨酸特异性去甲基化酶1抑制剂的应用 |
| SG11201608340UA (en) | 2014-04-11 | 2016-11-29 | Takeda Pharmaceuticals Co | Cyclopropanamine compound and use thereof |
| US10603295B2 (en) | 2014-04-28 | 2020-03-31 | Massachusetts Eye And Ear Infirmary | Sensorineural hair cell differentiation |
-
2015
- 2015-04-09 SG SG11201608340UA patent/SG11201608340UA/en unknown
- 2015-04-09 PH PH1/2016/502016A patent/PH12016502016B1/en unknown
- 2015-04-09 EA EA201692052A patent/EA034197B1/ru not_active IP Right Cessation
- 2015-04-09 TN TN2016000418A patent/TN2016000418A1/en unknown
- 2015-04-09 TW TW104111396A patent/TWI669291B/zh active
- 2015-04-09 NZ NZ725262A patent/NZ725262A/en unknown
- 2015-04-09 MX MX2016013369A patent/MX375990B/es active IP Right Grant
- 2015-04-09 CA CA2945085A patent/CA2945085C/en active Active
- 2015-04-09 AU AU2015244698A patent/AU2015244698B2/en active Active
- 2015-04-09 UA UAA201611450A patent/UA122205C2/uk unknown
- 2015-04-09 US US15/302,405 patent/US10053456B2/en active Active
- 2015-04-09 PE PE2016001947A patent/PE20161441A1/es unknown
- 2015-04-09 EP EP15721046.9A patent/EP3129369A1/en not_active Withdrawn
- 2015-04-09 SG SG10201808780YA patent/SG10201808780YA/en unknown
- 2015-04-09 CR CR20160485A patent/CR20160485A/es unknown
- 2015-04-09 MY MYPI2016703700A patent/MY180575A/en unknown
- 2015-04-09 WO PCT/JP2015/061651 patent/WO2015156417A1/en not_active Ceased
- 2015-04-09 US US14/682,695 patent/US9487511B2/en active Active
- 2015-04-09 BR BR112016023382-4A patent/BR112016023382B1/pt active IP Right Grant
- 2015-04-09 UY UY0001036071A patent/UY36071A/es not_active Application Discontinuation
- 2015-04-09 KR KR1020167029899A patent/KR102359836B1/ko active Active
- 2015-04-09 CN CN201580031044.3A patent/CN106459024B/zh active Active
- 2015-04-09 MA MA039732A patent/MA39732A/fr unknown
- 2015-04-09 AR ARP150101073A patent/AR099994A1/es active IP Right Grant
- 2015-04-09 JP JP2016561879A patent/JP6470310B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-06 US US15/203,522 patent/US9718814B2/en not_active Expired - Fee Related
- 2016-07-06 US US15/203,551 patent/US9714241B2/en not_active Expired - Fee Related
- 2016-09-20 US US15/270,863 patent/US9920047B2/en active Active
- 2016-10-05 IL IL248181A patent/IL248181B/en active IP Right Grant
- 2016-10-07 DO DO2016000273A patent/DOP2016000273A/es unknown
- 2016-10-07 CL CL2016002573A patent/CL2016002573A1/es unknown
- 2016-11-10 ZA ZA2016/07773A patent/ZA201607773B/en unknown
- 2016-11-11 EC ECIEPI201687256A patent/ECSP16087256A/es unknown
-
2018
- 2018-01-29 US US15/882,386 patent/US10414761B2/en active Active
-
2019
- 2019-06-27 US US16/455,359 patent/US10968213B2/en active Active
-
2021
- 2021-02-16 US US17/176,861 patent/US20210179603A1/en not_active Abandoned
-
2023
- 2023-08-14 US US18/449,326 patent/US20240317733A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161441A1 (es) | Compuesto de ciclopropanamina y sus usos | |
| CO2019007711A2 (es) | N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| AR063451A1 (es) | Diazabiciclo alcanos como receptores nicotinicos de acetilcolina. composiciones farmaceuticas. | |
| JP2014523851A5 (enExample) | ||
| CA2887598A1 (en) | Cyclopropanamine compound and use thereof | |
| JP2016505637A5 (enExample) | ||
| JP2017538785A5 (enExample) | ||
| BR112014026643A2 (pt) | derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta | |
| NZ604831A (en) | Apoptosis signal-regulating kinase inhibitors | |
| JP2014514286A5 (enExample) | ||
| JP2019525899A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2015516427A5 (enExample) | ||
| JP2010526106A5 (enExample) | ||
| JP2013063968A5 (enExample) | ||
| NZ598750A (en) | Therapeutic agent for mood disorders | |
| SI1919465T1 (en) | GSK-3 INHIBITORS | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| HRP20191744T1 (hr) | 1-[2-(aminometil)benzil]-2-tiokso-1,2,3,5-tetrahidro-4h-pirolo[3,2-d]pirimidin-4-oni kao inhibitori mijeloperoksidaze | |
| JP2017500289A5 (enExample) | ||
| JP2017505293A5 (enExample) | ||
| JP2013539774A5 (enExample) | ||
| RU2015101210A (ru) | Производные тиофена, используемые для лечения сахарного диабета | |
| JP2016540811A5 (enExample) | ||
| JP2015516419A5 (enExample) |